Pharmaceutical network August 4 news 160 medicines or will give up production!
▍ 32 drug firms, 160 product plan does not do consistency evaluation
On August 2, zhejiang provincial food and drug administration issued a report on the quality and efficacy of generic drugs in zhejiang province. According to the information, there are 32 pharmaceutical companies and 160 drug plans do not carry out generic drug consistency evaluation.
Released on March 5, 2016, the state council general office on the evaluation opinions of generics effect quality and consistency, and require all approved before October 1, 2007 listed in the national list of essential medicines (2012 edition) of chemicals generics oral solid preparation, consistency in principle should be completed by the end of 2018.
Encourage enterprises to carry out the consistency evaluation at the same time, through consistency evaluation of drug varieties, in terms of payment shall be the appropriate support, medical institutions should be prior purchasing and preferential treatment in the clinical.
The production enterprises with the consistency evaluation of the same variety of drugs have reached more than 3, and the varieties with no consistency evaluation are not selected in the areas of drug concentration procurement.
▍ a product 6 million, these generic drug or abandoned
It's a process of picking winners and losers. According to industry people, the cost of making a product consistency evaluation is about 6 million RMB, and some products are not worth doing and need to be measured.
Products with a lot of competing products and thin margins may be chosen by enterprises to give up and use the money in the advantage products.
As the 160 products listed in zhejiang province, basically meet the above conditions. For example, such products as norfloxacin, analgin, and other products, commonly known as the big drug, the drug companies choose to give up the original intention of the consistency evaluation, but it is not cost-effective, and presumably they are also ready to stop production.
▍ who would hold out until the last
The implication is that for the same kind of products, some of them are ready to give up the products. The empty market will be left to the last company, and the rewards will be generous.
Even if all the manufacturers are willing to produce, there is still the safeguard mechanism of shortage medicine, the country can be fixed point production, underwriting. So maybe some of these products will give up, but not disappear.
Attached: 160 medical information
